Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer
- 31 January 2009
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 63 (1) , 128-135
- https://doi.org/10.1016/j.lungcan.2008.05.001
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Predictive and prognostic value of FDG‐PET in nonsmall‐cell lung cancerCancer, 2007
- Emerging drugs for non-small-cell lung cancerEmerging Drugs, 2007
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Clinical Cancer Advances 2006: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical OncologyJournal of Clinical Oncology, 2007
- Non-Small Cell Lung Cancer GuidelinesJournal of the National Comprehensive Cancer Network, 2006
- Antiangiogenic drugs in non-small cell lung cancer treatmentCurrent Opinion in Oncology, 2006
- Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2005
- American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003Journal of Clinical Oncology, 2004
- Positron Emission Tomography in Non–Small-Cell Lung Cancer: Prediction of Response to Chemotherapy by Quantitative Assessment of Glucose UseJournal of Clinical Oncology, 2003
- The international system for staging lung cancerSeminars in Surgical Oncology, 2000